DNA RNA and Cells

09 May 2017 Eyevensys Announces the First-in-Human Treatment with its GroundBreaking EyeCET ElectroTransfection Technology for Eye Diseases
03 May 2017 Pluristem Announces Promising Results from Non-Human Primate Pilot Study of PLX-R18 in Acute Radiation Syndrome
03 May 2017 Rigontec Starts First-In-Human, Phase I/II Trial of RIG-I Agonist RGT100 and Appoints Eugen Leo as Chief Medical Officer
03 May 2017 ZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia
02 May 2017 Atlantic Healthcare initiates FDA rolling submission of its New Drug Application for alicaforsen in the treatment of pouchitis
28 Apr 2017 miRagen Therapeutics Presents Interim Results from MRG-201 Phase 1 Clinical Trial Demonstrating Pharmacodynamic Activity in Human Skin Incisions
28 Apr 2017 Moderna Announces Positive Interim Phase 1 Clinical Data Demonstrating First mRNA Vaccine Candidate, mRNA-1440, Induces High Levels of Immunogenicity
27 Apr 2017 The Medicines Company and Alnylam Pharmaceuticals Announce Agreement with FDA on Phase III Clinical Program for Inclisiran
26 Apr 2017 First patient treated in Turnstone's lung cancer trial combining novel viral cancer therapy with approved checkpoint inhibitor
25 Apr 2017 Voyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
25 Apr 2017 Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy
24 Apr 2017 Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
24 Apr 2017 SillaJen And Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial For Pexa-Vec in Advanced Liver Cancer
24 Apr 2017 Daiichi Sankyo Announces Designation of Duchenne Muscular Dystrophy Treatment DS-5141 under “SAKIGAKE Designation System”
24 Apr 2017 GangaGen Presents New Preclinical Data on P128 at ECCMID 2017 Showing Potent Bactericidal Activity Against MRSA and Other Staphylococci
22 Apr 2017 Arbutus Announces ARB-1467 Data Presentation at EASL
22 Apr 2017 Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
21 Apr 2017 Atara Bio Announces Positive Interim Results from Ongoing Phase 1 Trial of the Autologous Version of ATA188 in Patients with Primary and Secondary Progressive Multiple Sclerosis (MS) at the American Academy of Neurology (AAN) Annual Meeting 2017
21 Apr 2017 Promethera Biosciences Presents Preclinical Data on Novel H2Stem Cell Therapy at EASL International Liver Congress
20 Apr 2017 uniQure Announces It Will Not Seek Marketing Authorization Renewal for Glybera in Europe
20 Apr 2017 High Response and Remission Rates in Anti-TNFα Naïve Patients Treated with Qu Biologics’ Novel Immune Therapy for Crohn’s Disease
20 Apr 2017 Eyevensys Receives Approval From the UK Medicines and Healthcare Products Regulatory Agency to Advance its EyeCET Platform Into Clinical Development
18 Apr 2017 Enzyvant Receives FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy Designation for Investigational Therapy RVT-802
18 Apr 2017 Novartis CAR-T cell therapy CTL019 receives FDA Breakthrough Therapy designation for treatment of adult patients with r/r DLBCL
14 Apr 2017 AOBiome Completes Patient Enrollment In Phase 2 Clinical Trial Of Lead Candidate B244 To Treat Elevated Blood Pressure

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing